1. Search Result
Search Result
Results for "

β-Nicotinamide+Adenine+Dinucleotide

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Fluorescent Dyes

5

Biochemical Assay Reagents

8

Peptides

2

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0445
    NAD+
    40+ Cited Publications

    β-DPN; β-NAD; β-Nicotinamide Adenine Dinucleotide

    Endogenous Metabolite Metabolic Disease
    NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+
  • HY-B0445A
    NAD sodium
    40+ Cited Publications

    β-DPN sodium; β-NAD sodium; β-Nicotinamide Adenine Dinucleotide sodium

    Endogenous Metabolite Metabolic Disease
    NAD sodium is an orally effective cofactor and homeostatic regulator. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions that oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria, which indirectly generates ATP. NAD sodium can be used for the research of non-alcoholic fatty liver disease, obesity, and glucose intolerance .
    NAD sodium
  • HY-P4070

    Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
    Insulin icodec
  • HY-W654288

    β-DPN-d4; β-NAD-d4; β-Nicotinamide Adenine Dinucleotide-d4

    Isotope-Labeled Compounds Others
    NAD+-d4 is the deuterium-labeled NAD+ (HY-B0445). NAD+-d4 is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+-d4
  • HY-B0445S

    β-DPN-13C5 ammonium; β-NAD-13C5 ammonium; β-Nicotinamide Adenine Dinucleotide-13C5 ammonium

    Isotope-Labeled Compounds Metabolic Disease
    NAD+-13C5 (ammonium) is the 13C labled NAD+ (HY-B0445), with an ammonium .
    NAD+-13C5 ammonium
  • HY-B0445GL

    β-DPN (GMP Like); β-NAD (GMP Like); β-Nicotinamide Adenine Dinucleotide (GMP Like)

    Endogenous Metabolite Metabolic Disease
    NAD+ (GMP Like) is NAD+ (HY-B0445) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+ (GMP Like)
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-137672A

    2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate

    Phosphodiesterase (PDE) Calcium Channel Neurological Disease
    2',3'-Cyclic NADP disodium (2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate) is a substrate for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), an enzyme abundant in myelin. It has been used in a coupled enzyme assay to quantify CNP activity. 2',3'-Cyclic NADP disodium (5 μM) increases calcium overload-induced calcium release and prevents calcium-induced swelling in rat brain mitochondria.
    2',3'-Cyclic NADP disodium
  • HY-W250154

    Endogenous Metabolite Metabolic Disease
    β-Nicotinamide adenine dinucleotide reduced dipotassium is an orally active reduced coenzyme. β-Nicotinamide adenine dinucleotide reduced dipotassium is a donor of ADP-ribose units in ADP-ribosylaton reactions and a precursor of cyclic ADP-ribose. β-Nicotinamide adenine dinucleotide reduced dipotassium plays a role as a regenerative electron donor in cellular energy metabolism, including glycolysis, β-oxidation and the tricarboxylic acid (TCA) cycle .
    β-Nicotinamide adenine dinucleotide reduced dipotassium
  • HY-W250163
    NAD+ lithium
    40+ Cited Publications

    β-DPN lithium; β-NAD lithium; β-Nicotinamide Adenine Dinucleotide lithium

    Biochemical Assay Reagents Metabolic Disease
    NAD+ lithium (β-DPN lithium) is a lithium salt of nicotinamide adenine dinucleotide. NAD+ is a coenzyme in the REDOX reaction. NAD+ can directly or indirectly affect several key cellular functions, including metabolic pathways, DNA repair, chromatin remodeling, cell aging, and immune cell function .
    NAD+ lithium
  • HY-B0445AR

    β-DPN sodium (Standard); β-NAD sodium (Standard); β-Nicotinamide Adenine Dinucleotide sodium (Standard)

    Endogenous Metabolite Reference Standards Metabolic Disease
    NAD sodium (Standard) is the analytical standard of NAD sodium. This product is intended for research and analytical applications. NAD (β-Nicotinamide Adenine Dinucleotide) sodium is an analogue of NAD. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions which oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria that indirectly generates ATP .
    NAD sodium (Standard)
  • HY-177842

    Liposome Metabolic Disease
    Liposomal NAD+ is a specialized delivery system that encapsulates NAD+ within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of NAD+. NAD+ (β-Nicotinamide adenine dinucleotide), also known as Coenzym
    Liposomal NAD+
  • HY-P1103A

    CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-P4757

    Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-P11293

    Melanocortin Receptor Cancer
    DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .
    DOTA-GGNle-CycMSHhex
  • HY-P1321

    1229U91; GW1229

    Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-P1321A

    1229U91 TFA; GW1229 TFA

    Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA
  • HY-P11480

    Trk Receptor Neurological Disease
    TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC50: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .
    TrkA/NGF-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: